# AIRS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/airs

- Industry: Medical Devices & Equipment
- Headquarters: Daegu, South Korea
- Website: https://airobotsurgery.kr/
- Total disclosed funding: $3.5M
- Latest round: Series A (Mar 11, 2025)
- Investors on record: 5

## About

AIRS, Inc. specializes in developing advanced robotic surgical systems that enhance surgical precision and efficiency, enabling minimally invasive procedures for improved patient outcomes.AIRS, Inc. was founded in 2020 in Daegu, South Korea, focusing on robotic surgical technologies. The company has successfully completed 1 deal as of March 11, 2025, and raised KRW 5 billion in a Series A funding round, led by L&S Venture Capital with participation from other investors. The founder has not been specifically mentioned, and there are no known prior companies founded by them. The company operates primarily from its headquarters in Daegu, South Korea.The company specializes in advanced robotic surgical systems designed to enhance precision and efficiency in medical procedures. Their core product offerings include surgical robots equipped with cutting-edge imaging technology, enabling surgeons to perform minimally invasive operations with greater accuracy. These systems aim to address critical challenges in surgery, such as reducing recovery times and minimizing surgical complications, thus improving patient outcomes. The company primarily caters to hospitals and surgical centers across North America and Europe, targeting a diverse client base that includes healthcare providers seeking to adopt innovative surgical technologies. Additionally, their products are utilized by specialized surgeons in fields such as urology, gynecology, and general surgery, ensuring that a wide range of medical conditions can be effectively treated with their robotic solutions.The company generates revenue through the sale of its robotic surgical systems and associated service agreements, which may include maintenance and support contracts. Transactions typically occur through direct sales to hospitals and healthcare facilities, as well as partnerships with medical device distributors. Pricing structures for these advanced systems often involve a combination of upfront purchase costs and ongoing service fees, reflecting the sophisticated nature of the technology and the value it provides to end users. The flagship product, known for its precision and reliability, is positioned to command a premium price within the market, catering to healthcare institutions that are investing heavily in state-of-the-art surgical technologies. Overall, the company's revenue model is built on a foundation of strong client relationships and the ongoing need for innovative healthcare solutions.In March 2025, AIRS, Inc. raised KRW 5 billion in Series A funding to support technology commercialization and global expansion. The company plans to launch new robotic surgical products, although specific release dates have not been mentioned. Additionally, AIRS, Inc. aims to expand into new markets and regions, targeting additional territories in North America and Europe by the end of 2026.

## Funding rounds

- Series A, Mar 11, 2025, $3.5M — SL Investment, Korea Technology Finance Corporation, L&S Venture Capital, ReInvestment, ON Venture Investment

## Investors

- SL Investment (https://capitalatlas.ai/funds/sl-investment) — Series A
- Korea Technology Finance Corporation — Series A
- L&S Venture Capital (https://capitalatlas.ai/funds/l-s-venture-capital) — Series A
- ReInvestment (https://capitalatlas.ai/funds/reinvestment) — Series A
- ON Venture Investment (https://capitalatlas.ai/funds/on-venture-investment) — Series A